Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Rhea-AI Summary

Oncolytics Biotech (NASDAQ:ONCY), a clinical-stage immunotherapy company focused on developing pelareorep, has announced its participation in two upcoming investor conferences in September 2025. CEO Jared Kelly will engage with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference on September 9-10 and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11.

Both events will take place in New York City, with management conducting one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting the company directly.

SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Oncolytics Biotech^® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27^th Annual Global Investment Conference and the Lake Street Capital Markets 9^th Annual Best Ideas Growth Conference. Additional details for both of these events can be found below.

Event: H.C. Wainwright 27^th Annual Global Investment Conference
Date: Tuesday and Wednesday, September 9 & 10, 2025
Location: Lotte New York Palace Hotel, New York, NY

Event: Lake Street Capital Markets 9^th Annual Best Ideas Growth Conference
Date: Thursday, September 11, 2025
Location: The Yale Club, New York, NY

Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Lake Street Capital Markets representative, or email jpatton@oncolytics.ca. 

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.

Company Contact 
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca 

Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com 

Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com 

Logo: https://mma.prnewswire.com/media/2408622/5481159/Oncolytics_Biotech_Inc_Logo.jpg

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-investor-conferences-in-september-302540829.html

SOURCE Oncolytics Biotech® Inc.

FAQ

When and where will Oncolytics Biotech (ONCY) present at the H.C. Wainwright Conference in 2025?

Oncolytics Biotech will participate in the H.C. Wainwright Conference on September 9-10, 2025 at the Lotte New York Palace Hotel in New York.

How can investors schedule meetings with Oncolytics Biotech (ONCY) management at the September 2025 conferences?

Investors can schedule meetings through the conference websites, by contacting H.C. Wainwright or Lake Street Capital Markets representatives, or by emailing jpatton@oncolytics.ca.

What is Oncolytics Biotech's (ONCY) main product in development?

Oncolytics Biotech is developing pelareorep, as a clinical-stage immunotherapy treatment.

Which investor conferences will Oncolytics Biotech (ONCY) attend in September 2025?

Oncolytics Biotech will attend the H.C. Wainwright 27th Annual Global Investment Conference (Sept. 9-10) and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (Sept. 11).